Everything below concerns GHRH analog. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
| Property | Value | Notes |
|---|---|---|
| Primary marker | Insulin-like growth factor 1 | Slow-changing integrated indicator of axis activity |
| Secondary marker | Growth hormone | Pulsatile; requires repeated or timed sampling |
| Typical analytical method | Immunoassay | Antibody-based quantification in serum |
| Common sample matrix | Serum | Collected under standardized conditions |
| Key interpretation factor | Age-stratified reference ranges | Baseline marker concentrations shift with age |
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
== Political composition == It was possible for the ILEA to have a majority of Labour members when the GLC had a majority of Conservative members, and this happened from 1970 to 1973 and 1977 to 1981. In addition, most of the important decisions taken by the ILEA were taken by its Education Committee, on which every member sat. The Education Committee could also co-opt members with experience of education, some of them representing the teaching unions. The initial composition of the ILEA in 1964 was 43 Labour members to 9 Conservatives, with one Independent. After the 1967 election the Conservatives won a majority, and Christopher Chataway became Leader. However, Labour won control in 1970 and Ashley Bramall began his long leadership. His term saw the ILEA go over to comprehensive education, and the abolition of school corporal punishment. He retained power despite the Conservative election victory in the 1977 GLC elections. When the Left, under Ken Livingstone, won control of the GLC after the 1981 elections, Bramall lost his position in an internal Labour Party vote, being replaced by Bryn Davies. Livingstone later expressed regret for this decision and expressed his admiration for Bramall's leadership abilities. The remaining years of the ILEA saw a succession of left-wing leaderships, none of which lasted long or established a strong reputation. Frances Morrell, formerly an assistant to Tony Benn, led a feminist ILEA from 1983 to 1987 which threatened to defy its rate-capping in November 1984, before Neil Fletcher took over.
=== Dextran hydrogel colon-targeting === The colon is an ideal target for dextran hydrogel drug delivery systems due to the presence of dextranases. Dextran can be cross-linked with diisocyanate to form a hydrogel that can be loaded with hydrocortisone to treat swelling or inflammation in the colon. Hydrogels can also be synthesized from crosslinking epichlorohydrin (ECH) with dextran. Dextran-ECH hydrogels can be loaded with salmon calcitonin (sCT) to treat bone diseases. Dextran-ECH hydrogels loaded with sCT achieved comparable release rates to other polymeric hydrogels in the colon.
== Structures involved in clinical attachment loss == Clinical attachment loss refers to the apical migration and destruction of the tissues that secure the tooth within the periodontium. This process involves the coordinated breakdown of epithelial, connective tissue, and osseous components that collectively form the periodontal attachment apparatus.
== See also == Glycogen storage disease Hitting the wall (muscle fatigue due to glycogen depletion) Inborn errors of carbohydrate metabolism Purine nucleotide cycle§Glycogenoses (GSDs) Second wind (increased ATP production primarily by fatty acids after glycogen depletion)
Sources: en.wikipedia.org
=== Lawsuits === From 2019 to 2024, Maria Francesca Gioia, a former medical student acting as a pro se plaintiff, filed nine product liability lawsuits against Janssen Pharmaceuticals and related parties. She alleged that taking Invega Sustenna (paliperidone palmitate) caused her memory loss, hypothyroidism, Horner's syndrome, nerve damage, motor tremors, vocal tics, confusion, loss of taste and sensation, post-traumatic stress disorder, and metabolic syndrome (including hypertension, diabetes, and stroke), which ended her career as a primary care physician. All nine lawsuits were dismissed on procedural grounds: Gioia I–II for failure to state a claim, Gioia III for failure to prosecute, and Gioia IV–V for lack of subject matter jurisdiction. The court also noted that the side effects she alleged were already listed on Invega's FDA-approved warning label. In September 2024, Cassandra Fameux filed a criminal complaint alleging that her husband, a Michigan anesthesiologist, had forcibly injected her with unprescribed Invega Sustenna on multiple occasions between 2017 and 2021. A subsequent police investigation led to a recommendation that he be charged with domestic assault. In May and June 2022, Adilah Patton, a 28‑year‑old pretrial detainee in Indianapolis, was forcibly injected twice with unprescribed Invega Sustenna while in custody at the Marion County Adult Detention Center. A federal lawsuit filed on her behalf alleges that the injections were administered without a medical assessment, a prescription, or the consent of her court‑appointed guardian.
An agonist is a chemical capable of binding to a receptor, such as a neurotransmitter receptor, and initiating the same reaction typically produced by the binding of the endogenous substance. An agonist of a neurotransmitter will thus initiate the same receptor response as the transmitter. In neurons, an agonist drug may activate neurotransmitter receptors either directly or indirectly. Direct-binding agonists can be further characterized as full agonists, partial agonists, inverse agonists. Direct agonists act similar to a neurotransmitter by binding directly to its associated receptor site(s), which may be located on the presynaptic neuron or postsynaptic neuron, or both. Typically, neurotransmitter receptors are located on the postsynaptic neuron, while neurotransmitter autoreceptors are located on the presynaptic neuron, as is the case for monoamine neurotransmitters; in some cases, a neurotransmitter utilizes retrograde neurotransmission, a type of feedback signaling in neurons where the neurotransmitter is released postsynaptically and binds to target receptors located on the presynaptic neuron. Nicotine, a compound found in tobacco, is a direct agonist of most nicotinic acetylcholine receptors, mainly located in cholinergic neurons. Opiates, such as morphine, heroin, hydrocodone, oxycodone, codeine, and methadone, are μ-opioid receptor agonists; this action mediates their euphoriant and pain relieving properties.
=== Climate change === Bhutto Zardari has proposed a plan to "completely restructure Pakistan's economic development model, putting the threat of climate change front and centre." His party's election manifesto aims to ensure that funds exceeding $10 billion are directed to fighting climate change, in the wake of the 2022 Pakistan floods that displaced more than 7 million people.
Sources: en.wikipedia.org
The Treaty of Tilsit in 1807 resulted in the Anglo–Russian War (1807–1812). Emperor Alexander I declared war on Britain after the British attack on Denmark in September 1807. British men-of-war supported the Swedish fleet during the Finnish War and won victories over the Russians in the Gulf of Finland in July 1808 and August 1809. The success of the Russian army on land, however, forced Sweden to sign peace treaties with Russia in 1809 and with France in 1810, and to join the blockade against Britain. But Franco–Russian relations would become progressively worse after 1810, and the Russian war with Britain effectively ended. In April 1812, Britain, Russia, and Sweden signed secret agreements directed against Napoleon. The central issue for both Emperor Napoleon I and Tsar Alexander I was control over Poland. Each wanted a semi-independent Poland he could control. As Esdaile notes, "Implicit in the idea of a Russian Poland was, of course, a war against Napoleon." Schroeder says Poland was "the root cause" of Napoleon's war with Russia, but Russia's refusal to support the Continental System was also a factor. In 1812, at the height of his power, Napoleon invaded Russia with a pan-European Grande Armée, consisting of 450,000 men (200,000 Frenchmen, and many soldiers of allies or subject areas). The French forces crossed the Niemen river on 24 June 1812. Russia proclaimed a Patriotic War, and Napoleon proclaimed a Second Polish war.
=== Oxidative half === In the oxidative half of the mechanism, Cys63 nucleophilically attacks the nearest sulfide unit in the GSSG molecule (promoted by His467), which creates a mixed disulfide bond (GS-Cys58) and a GS− anion. His467 of GSR then protonates the GS- anion to release the first molecule of GSH. Next, Cys63 nucleophilically attacks the sulfide of Cys58, releasing a GS− anion, which, in turn, picks up a solvent proton and is released from the enzyme, thereby creating the second GSH. So, for every GSSG and NADPH, two reduced GSH molecules are gained, which can again act as antioxidants scavenging reactive oxygen species in the cell.
=== Pharmacokinetics === Topilutamide is a topical medication and is applied to the scalp. Topilutamide degrades in human serum at 37 °C with a half-life of approximately 6 hours and is undetectable after 48 hours. Perfluoroacylamido-arylpropanamides decompose hydrolytically to BP-34 and their corresponding perfluorocarboxylic acid. In the case of topilutamide, that perfluorocarboxylic acid is trifluoroacetic acid. The two metabolites of topilutamide namely BP-34 and trifluoroacetic acid were undetectable in human serum (below the detection limit of 5 ng/mL) along with the parent compound topilutamide, in human studies. BP-34 was shown to be devoid of anti-androgenic activity.
Sources: en.wikipedia.org
It varies slowly and reflects cumulative axis activity rather than momentary secretion. Growth hormone is released in pulses affected by sleep, stress, and meals, making single readings hard to interpret. The slower marker gives a more stable picture across a study period.
Assay calibration and antibody specificity differ between platforms, so identical samples can yield different numbers. A method change within one laboratory can shift results without any biological change. Cross-validation is often needed for multi-site work.
They capture only one moment in a pulsatile pattern and are strongly influenced by recent activity and meals. Repeated sampling or overnight profiles provide a more representative view. Provocative testing is an alternative when a dynamic response is of interest.
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.